What changed: Locally advanced and metastatic basal cell carcinoma
Every dated change on the records linked to Locally advanced and metastatic basal cell carcinoma, newest first: approvals and regulatory steps on its medicines, trials that reported, guideline versions, milestones, and when this page itself was checked. Dates come from the records; none is inferred. Orientation, not medical advice.
September 2026 · 1
February 2021 · 1
2021 · 1
2017 · 1
2015 · 3
- 2015ApprovalSonidegibSonidegib approved in US
Locally advanced BCC recurrent after surgery or radiation, or not candidates
- 2015Trial resultBOLTBOLT reported
Objective response at 200 mg: 43% in locally advanced and 15% in metastatic basal cell carcinoma (central review).
- 2015MilestoneBOLTBOLT: sonidegib approved
A milestone in how this cancer is treated.
2012 · 3
- 2012ApprovalVismodegibVismodegib approved in US
Metastatic BCC or locally advanced BCC recurrent after surgery or not amenable to surgery/radiation
- 2012Trial resultERIVANCE BCCERIVANCE BCC reported
Objective response 43% in locally advanced and 30% in metastatic basal cell carcinoma (independent review).
- 2012MilestoneERIVANCE BCCERIVANCE: vismodegib approved, the first hedgehog inhibitor
A milestone in how this cancer is treated.